Amgen Effort To Reclaim Procrit Rights From J&J Moving To Trial Phase
Executive Summary
Amgen will receive a trial in its arbitration claim seeking to terminate Johnson & Johnson's license to sell Procrit in the U.S., but appears to have a difficult burden to meet before the arbitration panel.
You may also be interested in...
Split Indication Deals Are Lose-Lose For Partnering Firms, Boehringer Says
Companies should be wary of split indication agreements for products due to the complexities of such deals in practice, Boehringer Ingelheim Alliance Management Director Brooke Paige said Aug. 9
Split Indication Deals Are Lose-Lose For Partnering Firms, Boehringer Says
Companies should be wary of split indication agreements for products due to the complexities of such deals in practice, Boehringer Ingelheim Alliance Management Director Brooke Paige said Aug. 9
Split-Indication Agreements: Happy Unions Or Problematic Proposals?
Greater restrictions on off-label promotions and continued cost pressures are creating an environment ripe for alliances based around single products with split indications, industry executives said during the Windhover Pharmaceutical Strategic Outlook conference in New York March 27-29